Abstract
As a child, I reluctantly submitted to routine vaccinations at my pediatrician's office, much as my own patients do today.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 689-693 |
| Number of pages | 5 |
| Journal | Human vaccines |
| Volume | 6 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2010 |
Funding
R&D mission creep for VFC can be rectified by enhancing federal support for ongoing vaccine R&D to academic groups, biotechnology firms and pharma ceutical manufacturers from agencies such as the National Institutes of Health and and Department of Defense. Such funding sources have been reliable for early-phase research on vaccines in the past but must provide greater support in the future for clinical trials, in order to avoid the oft-described ‘valley of death’ in which promising preclinical products fail in the R&D pipeline because of insufficient funds to carry the work into humans. Funding of this nature would effectively lift the burden of such support off the shoulders of the VFC program, allowing it to focus on the value of recommended vaccines in immediate medical and public health applications and how that value should translate to product price.
Keywords
- Economics
- Market
- Policy
- Vaccines
- Vaccines for children program
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics(all)
- Immunology
